Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

NCT00390416 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms
Esophageal Neoplasms

Interventions

DRUG: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]